Spots Global Cancer Trial Database for daratumumab
Every month we try and update this database with for daratumumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | NCT05280275 | Multiple Myelom... Neoplasms Neoplasms, Plas... Gammopathy, Mon... Paraproteinemia... Blood Protein D... Haematologic Di... Corneal Disease | Belantamab Mafo... Daratumumab Lenalidomide Dexamethasone | 18 Years - | Hellenic Society of Hematology | |
| Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) | NCT02955810 | Multiple Myelom... | Daratumumab Cyclophosphamid... Bortezomib Dexamethasone | 18 Years - 70 Years | National University of Ireland, Galway, Ireland | |
| Daratumumab in Treating Patients With Multiple Myeloma | NCT02944565 | Plasma Cell Mye... | Daratumumab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone | NCT03180736 | Multiple Myelom... | Daratumumab Pomalidomide Dexamethasone | 18 Years - | Stichting European Myeloma Network | |
| A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma | NCT05590377 | Multiple Myelom... | Modakafusp Alfa Daratumumab | 18 Years - | Takeda | |
| Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis | NCT02816476 | Amyloidosis | Daratumumab | 18 Years - | University Hospital, Limoges | |
| Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT | NCT05218603 | Multiple Myelom... Non-eligible fo... | Bortezomib Daratumumab | 18 Years - | PETHEMA Foundation | |
| A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | NCT04722146 | Multiple Myelom... | Teclistamab Daratumumab Pomalidomide Lenalidomide Bortezomib Nirogacestat | 18 Years - | Janssen Research & Development, LLC | |
| A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT06232707 | Multiple Myelom... | Alnuctamab Pomalidomide Daratumumab Elotuzumab Carfilzomib Dexamethasone | 18 Years - | Celgene | |
| Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM | NCT05408026 | Relapsed or Ref... | Daratumumab Pomalidomide | 18 Years - | Alliance Foundation Trials, LLC. | |
| A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type | NCT02927925 | Lymphoma | Daratumumab | 18 Years - | Janssen Research & Development, LLC | |
| Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) | NCT03221634 | Multiple Myelom... | Pembrolizumab Daratumumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma | NCT04151667 | Multiple Myelom... | Daratumumab Inj... Dexamethasone O... Lenalidomide Pi... Bortezomib Inje... | 65 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia | NCT03447808 | Chronic Lymphoc... | Daratumumab Ibrutinib Laboratory Biom... Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | NCT03314181 | Multiple Myelom... | Dexamethasone Daratumumab Venetoclax Bortezomib | 18 Years - | AbbVie | |
| A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma | NCT02541383 | Multiple Myelom... | Bortezomib (VEL... Bortezomib, Tha... Daratumumab | 18 Years - 65 Years | Intergroupe Francophone du Myelome | |
| Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer | NCT03473730 | Bladder Urothel... Clear Cell Rena... Malignant Urina... Metastatic Kidn... Stage IV Renal ... | Biopsy Daratumumab Laboratory Biom... Metastasectomy Nephrectomy | 18 Years - | M.D. Anderson Cancer Center | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial | NCT05497804 | ISS Stage III P... Plasma Cell Mye... | Bone Marrow Asp... Carfilzomib Computed Tomogr... Daratumumab Dexamethasone Lenalidomide Magnetic Resona... Positron Emissi... | 18 Years - 80 Years | Mayo Clinic | |
| A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma | NCT02773030 | Multiple Myelom... | CC-220 Dexamethasone Daratumumab Bortezomib Carfilzomib | 18 Years - | Celgene | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide | NCT05434689 | Multiple Myelom... | Iberdomide Daratumumab Dexamethasone Carfilzomib | 19 Years - | University of Alabama at Birmingham | |
| Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL) | NCT03207542 | Malignant Neopl... | Daratumumab | 18 Years - | M.D. Anderson Cancer Center | |
| Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma | NCT00574288 | Multiple Myelom... | Part 1: Daratum... Part 2: Daratum... Methylprednisol... Dexamethasone | 18 Years - | Janssen Research & Development, LLC | |
| Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma | NCT06042725 | Multiple Myelom... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Chest Radiograp... Computed Tomogr... Daratumumab Dexamethasone Lenalidomide Low Dose Comput... Magnetic Resona... Positron Emissi... Venetoclax X-Ray Imaging Questionnaire A... | 18 Years - | Mayo Clinic | |
| A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM | NCT05088330 | Newly Diagnosed... | Daratumumab | 18 Years - 70 Years | The First Affiliated Hospital of Soochow University | |
| Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT04975997 | Multiple Myelom... | Dexamethasone Daratumumab Bortezomib Iberdomide Iberdomide Iberdomide | 18 Years - | Celgene | |
| A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma | NCT03290950 | Multiple Myelom... | daratumumab carfilzomib lenalidomide dexamethasone dexamethasone | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia | NCT03591744 | Plasma Cell Leu... | Bortezomib Daratumumab Dexamethasone Lenalidomide Pegylated Lipos... | 18 Years - | City of Hope Medical Center | |
| MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | NCT05020236 | Multiple Myelom... | Elranatamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Pfizer | |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | NCT04065789 | Myeloma Multipl... Myeloma, Plasma... Myeloma-Multipl... Plasma Cell Mye... | Carfilzomib Daratumumab Lenalidomide Dexamethasone | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy | NCT03993912 | Multiple Myelom... | Daratumumab SC ... Lenalidomide PO... Dexamethasone P... | 65 Years - | University Hospital, Lille | |
| A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients | NCT04124497 | Multiple Myelom... Deletion 17P Sy... | Daratumumab Pomalidomide Dexamethasone | 18 Years - | Fondazione EMN Italy Onlus | |
| A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | NCT03384654 | Precursor Cell ... | Daratumumab Vincristine Prednisone Doxorubicin Peg-asparaginas... Cyclophosphamid... Cytarabine 6-mercaptopurin... Methotrexate | 1 Year - 30 Years | Janssen Research & Development, LLC | |
| Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. | NCT05527340 | Multiple Myelom... | Iberdomide Dexamethasone Daratumumab | 18 Years - | PETHEMA Foundation | |
| Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT03763162 | Recurrent Plasm... Refractory Plas... | Bortezomib Daratumumab Dexamethasone Ixazomib Quality-of-Life... | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) | NCT03221634 | Multiple Myelom... | Pembrolizumab Daratumumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone | NCT03180736 | Multiple Myelom... | Daratumumab Pomalidomide Dexamethasone | 18 Years - | Stichting European Myeloma Network | |
| A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | NCT04661137 | Multiple Myelom... | Selinexor 60 MG Selinexor 80 MG Selinexor 100 M... Carfilzomib Pomalidomide Daratumumab Dexamethasone | 18 Years - | Hackensack Meridian Health | |
| GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies | NCT04824794 | Relapsed or Ref... Diffuse Large B... Acute Myeloid L... | GEN3014 Daratumumab | 18 Years - | Genmab | |
| Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant | NCT03537599 | Minimal Residua... Recurrent Acute... Recurrent Adult... Recurrent Child... | Daratumumab Donor Lymphocyt... Laboratory Biom... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM | NCT05088330 | Newly Diagnosed... | Daratumumab | 18 Years - 70 Years | The First Affiliated Hospital of Soochow University | |
| A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma | NCT03290950 | Multiple Myelom... | daratumumab carfilzomib lenalidomide dexamethasone dexamethasone | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide | NCT05434689 | Multiple Myelom... | Iberdomide Daratumumab Dexamethasone Carfilzomib | 19 Years - | University of Alabama at Birmingham | |
| A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | NCT03314181 | Multiple Myelom... | Dexamethasone Daratumumab Venetoclax Bortezomib | 18 Years - | AbbVie | |
| A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma | NCT05243342 | Multiple Myelom... | XmAb24306 Daratumumab | 18 Years - | Genentech, Inc. | |
| Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM | NCT03481556 | Multiple Myelom... | Melphalan flufe... Dexamethasone Bortezomib Daratumumab | 18 Years - | Oncopeptides AB | |
| A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma | NCT02807454 | Multiple Myelom... | Daratumumab Durvalumab Pomalidomide Dexamethasone | 18 Years - | Celgene | |
| A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma | NCT04268498 | Multiple Myelom... | Bortezomib Dexamethasone Lenalidomide Acetaminophen Diphenhydramine Montelukast Carfilzomib Daratumumab Autologous Stem... | 18 Years - 75 Years | University of Miami | |
| Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma | NCT03500445 | Myeloma Multiple Myelom... | Daratumumab Carfilzomib Lenalidomide Dexamethasone | 18 Years - | University of Chicago | |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | NCT04065789 | Myeloma Multipl... Myeloma, Plasma... Myeloma-Multipl... Plasma Cell Mye... | Carfilzomib Daratumumab Lenalidomide Dexamethasone | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis | NCT04304144 | AL Amyloidosis | CAEL-101 SoC: cyclophosp... Daratumumab | 18 Years - | Alexion Pharmaceuticals, Inc. | |
| Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma | NCT03311828 | Recurrent Plasm... Plasma Cell Mye... Secondary Amylo... | Daratumumab Imaging Agent Positron Emissi... Pharmacological... | 18 Years - | City of Hope Medical Center | |
| A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma | NCT03697629 | Multiple Myelom... | Daratumumab | 18 Years - | Canadian Myeloma Research Group | |
| Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant | NCT03289299 | Smoldering Mult... | Carfilzomib Lenalidomide Daratumumab Dexamethasone | 18 Years - | International Myeloma Foundation | |
| A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | NCT02076009 | Multiple Myelom... | Daratumumab Lenalidomide Dexamethasone | 18 Years - | Janssen Research & Development, LLC | |
| A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | NCT05455320 | Relapsed or Ref... | Talquetamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Janssen Research & Development, LLC | |
| Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma | NCT02626481 | Multiple Myelom... | Daratumumab Dexamethasone | 18 Years - | University Hospital, Lille | |
| A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | NCT06413498 | Multiple Myelom... | Anitocabtagene ... Cyclophosphamid... Fludarabine Pomalidomide Bortezomib Dexamethasone Daratumumab Carfilzomib | 18 Years - | Gilead Sciences | |
| A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia | NCT03187262 | Waldenström Mac... | Daratumumab | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma | NCT04280328 | Multiple Myelom... | Ciforadenant daratumumab | 18 Years - 80 Years | Corvus Pharmaceuticals, Inc. | |
| STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | NCT03829371 | Multiple Myelom... | Velcade Melphalan Prednisone Lenalidomide Dexamethasone Daratumumab | 65 Years - | University of Turin, Italy | |
| Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy | NCT02852837 | Multiple Myelom... | Daratumumab | 18 Years - | Janssen Research & Development, LLC | |
| A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma | NCT02541383 | Multiple Myelom... | Bortezomib (VEL... Bortezomib, Tha... Daratumumab | 18 Years - 65 Years | Intergroupe Francophone du Myelome | |
| Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT03067571 | High Risk Myelo... Recurrent Acute... Refractory Acut... | Daratumumab | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy | NCT04140162 | Multiple Myelom... | Daratumumab Lenalidomide Bortezomib Dexamethasone | 18 Years - | University of Michigan Rogel Cancer Center | |
| Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | NCT03651128 | Multiple Myelom... | bb2121 Daratumumab Pomalidomide Dexamethasone Bortezomib Ixazomib Lenalidomide Carfilzomib Elotuzumab | 18 Years - | Celgene | |
| A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma | NCT03357952 | Multiple Myelom... | Daratumumab JNJ-63723283 | 18 Years - | Janssen Research & Development, LLC | |
| 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome | NCT06287944 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | Actinium Ac 225... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Daratumumab Echocardiograph... Fludarabine Hematopoietic C... Indium In 111-D... Melphalan Multigated Acqu... Radionuclide Im... Single Photon E... Sirolimus Tacrolimus Total Marrow an... | 18 Years - | City of Hope Medical Center | |
| Neoadjuvant Listeria or Daratumumab in Prostate Cancer | NCT03035357 | Malignant Neopl... Prostate Cancer | Daratumumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) | NCT02431208 | Multiple Myelom... | Atezolizumab (M... Daratumumab Lenalidomide Pomalidomide Dexamethasone | 18 Years - | Hoffmann-La Roche | |
| Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma | NCT05896228 | Refractory Mult... Relapsed Multip... | Iberdomide Carfilzomib Daratumumab Dexamethasone Acetaminophen Diphenhydramine Montelukast | 18 Years - 75 Years | University of Miami | |
| Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma | NCT04635189 | Multiple Myelom... | Daratumumab Lenalidomide Dexamethasone | 18 Years - 75 Years | University of Rochester | |
| Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma | NCT04205240 | Recurrent Plasm... | Allogeneic Hema... Cyclophosphamid... Daratumumab Fludarabine Melphalan Mycophenolate M... Tacrolimus | 18 Years - 75 Years | Ohio State University Comprehensive Cancer Center | |
| A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | NCT02195479 | Multiple Myelom... | Velcade Melphalan Prednisone Daratumumab IV Dexamethasone Daratumumab SC | 18 Years - | Janssen Research & Development, LLC | |
| NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma | NCT04136756 | Multiple Myelom... Non-Hodgkin Lym... Indolent Non-Ho... | NKTR-255 NKTR-255 Q21 Rituximab Daratumumab | 18 Years - 80 Years | Nektar Therapeutics | |
| Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT03701321 | Recurrent Plasm... Refractory Plas... | Bortezomib Daratumumab Dexamethasone Venetoclax | 18 Years - | National Cancer Institute (NCI) | |
| A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread | NCT03098550 | Advanced Cancer | Nivolumab Daratumumab | 18 Years - | Bristol-Myers Squibb | |
| Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma | NCT02874742 | Multiple Myelom... | Lenalidomide Bortezomib Dexamethasone Daratumumab | 18 Years - 70 Years | Janssen Research & Development, LLC | |
| Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma | NCT03477539 | Plasma Cell Mye... | Autologous Hema... Daratumumab Lenalidomide | 18 Years - | Mayo Clinic |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
